I'll have There now is much more here come Sunday, the 9th, but know now that Crestor is -- acoording to many Wall Street analysts -- widely expected to double its market share (~$3 billion per year in 2008, to ~$6 billion per year by 2012), as a result of the huge success of AstraZeneca's "Jupiter" study.
And it is very likely to take almost all of that share from Schering -- and Vytorin/Zetia.
More here, on Sunday -- from Louisiana.
Friday, November 7, 2008
Look for Crestor's "Jupiter" to Rock Schering -- on Sunday (and Monday, on the NYSE). . . .
Subscribe to:
Post Comments (Atom)
2 comments:
apparently there will be a scientific session at the meeting talking specifically about Vytorin.
And it looks like the AHA web-mavens will provide LIVE streaming video-feeds of the scientific sessions!
I'll be watching tomorrow, and on Sunday, for a Vytorin-specific session!
If the techs have it working at AHA, and such a session transpires, I'll open an anchored window on my site, to be able to view the video, right here.
Thanks -- great lead!
Post a Comment